Landos Biopharma (LABP)

Company Profile

Landos Biopharma is a clinical-stage biopharmaceutical company focused on the discovery and development of oral therapeutics for patients with autoimmune diseases that are the first to target new mechanisms of action, including the LANCL2, NLRX1 and PLXDC2 immunometabolic pathways. Landos Biopharma’s core expertise is in the development of therapeutic candidates targeting novel pathways at the interface of immunity and metabolism. Lead asset BT-11 is a novel, oral, gut-restricted small molecule therapeutic candidate for the treatment of ulcerative colitis and Crohn’s disease that targets the LANCL2 pathway. NX-13 is a novel, oral, gut-restricted compound for the treatment of inflammatory bowel disease, which targets the NLRX1 pathway. Additional candidates are in development for the treatment of lupus nephritis, rheumatoid arthritis, multiple sclerosis, and diabetes.

Company profile

Ticker

LABP

Exchange

NASDAQ

Website

www.landosbiopharma.com

Incorporated

Delaware

Location

Virginia

Fiscal year end

Dec 31

Sector

Manufacturing > Pharmaceutical Preparation Manufacturing

Industry (SIC)

Pharmaceutical Preparations

Pfizer • Johnson & Johnson • Merck & Co • Abbott Laboratories • Teva- Pharmaceutical Industries • Bristol-Myers Squibb • Lilly(Eli) & Co • Viatris • Abbvie • Bausch Health Companies ...

SEC CIK

0001785345

Corporate docs

Articles of Incorporation & Bylaws

Underwriting Agreements

Plans of Reorganization

Indentures

Material Contracts & Credit Agreements

IRS number

815085535

LABP stock data

1M 1Y 5Y

Analyst ratings and price targets

Last 3 months

Latest filings (excl ownership)

View all

S-8

Registration of securities for employees

Landos Biopharma Provides Business Update and Reports Fourth Quarter and Full Year 2022 Results

Asset Purchase and Redemption Agreement

28 Feb 23

8-K

Entry into a Material Definitive Agreement

13 Jan 23

8-K

Landos Biopharma Provides Comprehensive Update on Clinical Development Plans

5 Jan 23

8-K

Landos Biopharma Announces $16.7 Million Private Placement Financing

5 Jan 23

8-K

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard

10 Nov 22

Transcripts

LABP

Earnings call transcript

2021 Q3

15 Nov 21

Latest ownership filings

View all

Josep Bassaganya-Riera

Josep Bassaganya-Riera

14 Feb 23

SC 13G/A

Bassaganya-Riera Josep

14 Feb 23

SC 13D/A

PERCEPTIVE ADVISORS LLC

Financial summary

Financial statements Chart LABP financial data

Quarter (USD)	Dec 22	Sep 22	Jun 22	Mar 22
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Annual (USD)	Dec 22	Dec 21	Dec 20
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Cash burn rate (est.)	Burn method: Change in cash		Burn method: Operating income		Burn method: FCF (opex + capex)
	Last Q	Avg 4Q	Last Q	Avg 4Q	Last Q	Avg 4Q
Cash on hand (at last report)	36.64 mm	36.64 mm	36.64 mm	36.64 mm	36.64 mm	36.64 mm
Cash burn (monthly)	(no burn)	(no burn)	2.17 mm	3.39 mm	1.23 mm	3.81 mm
Cash used (since last report)	n/a	n/a	6.45 mm	10.06 mm	3.66 mm	11.33 mm
Cash remaining	n/a	n/a	30.19 mm	26.58 mm	32.98 mm	25.31 mm
Runway (months of cash)	n/a	n/a	13.9	7.8	26.7	6.6

Beta Read what these cash burn values mean

Financial data from company earnings reports.

Institutional ownership, Q4 2022

LABP institutional ownership history Ownership history

66.3% owned by funds/institutions

13F holders	Current	Prev Q	Change
Total holders	25	30	-16.7%
Opened positions	5	4	+25.0%
Closed positions	10	10	–
Increased positions	5	5	–
Reduced positions	7	11	-36.4%

13F shares	Current	Prev Q	Change
Total value	7.74 bn	22.79 mm	+33858.6%
Total shares	20.67 mm	26.48 mm	-22.0%
Total puts	0.00	0.00
Total calls	0.00	0.00
Total put/call ratio	–	–	–

Largest owners	Shares	Value	Change
Perceptive Advisors	14.87 mm	$7.43 bn	0.0%
Xontogeny	3.09 mm	$0.00	0.0%
Osage University GP III	1.83 mm	$8.77 mm	0.0%
MCQEF Macquarie	147.18 k	$74.00 mm	0.0%
Renaissance Technologies	125.40 k	$63.00 k	-51.5%
Vanguard	103.09 k	$51.56 mm	-38.1%
Bridgeway Capital Management	99.00 k	$49.51 mm	-33.6%
Green Square Capital Advisors	94.50 k	$47.26 mm	+11.8%
Geode Capital Management	92.24 k	$46.00 k	+18.9%
HRT Financial	52.56 k	$26.00 k	NEW

Largest transactions	Shares	Bought/sold	Change
RTW Investments	0.00	-3.98 mm	EXIT
OUP Management	0.00	-1.24 mm	EXIT
BLK Blackrock	24.38 k	-272.51 k	-91.8%
Renaissance Technologies	125.40 k	-133.30 k	-51.5%
Botty Investors	0.00	-127.26 k	EXIT
Vanguard	103.09 k	-63.52 k	-38.1%
HRT Financial	52.56 k	+52.56 k	NEW
Bridgeway Capital Management	99.00 k	-50.00 k	-33.6%
STT State Street	25.20 k	+25.20 k	NEW
Susquehanna International	21.06 k	+21.06 k	NEW

Data from 13F filings, for the last complete 13F reporting period. For most recent data, click the ownership history button. Values as filed, not updated for current price. Long positions only.

Recent insider trades

LABP insider ownership history Insider history

Date	Owner	Security	Transaction	Code	Indirect	10b5-1	$Price	#Shares	$Value	#Remaining
28 Feb 23	Patrick Truesdell	RSU Common Stock	Grant	Acquire A	No	No	0	99,600	0.00	99,600
28 Feb 23	Patrick Truesdell	Employee Stock Option Common Stock	Grant	Acquire A	No	No	0.37	99,600	36.85 k	99,600
28 Feb 23	Gregory Oakes	Employee Stock Option Common Stock	Grant	Acquire A	No	No	0.37	475,300	175.86 k	475,300
28 Feb 23	Fabio Cataldi	RSU Common Stock	Grant	Acquire A	No	No	0	276,750	0.00	276,750
28 Feb 23	Fabio Cataldi	Employee Stock Option Common Stock	Grant	Acquire A	No	No	0.37	184,500	68.27 k	184,500
28 Feb 23	Josep Bassaganya-Riera	common stock	Sell	Dispose S	Yes	No	0	786,299	0.00	0
28 Feb 23	Josep Bassaganya-Riera	common stock	Sell	Dispose S	Yes	No	0	500,000	0.00	0
28 Feb 23	Josep Bassaganya-Riera	common stock	Sell	Dispose S	Yes	No	0	496,527	0.00	0
28 Feb 23	Josep Bassaganya-Riera	common stock	Sell	Dispose S	Yes	No	0	467,306	0.00	0
28 Feb 23	Josep Bassaganya-Riera	common stock	Sell	Dispose S	Yes	No	0	3,470,736	0.00	0